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112 The Journal of Thoracic and Cardbjective: We sought to elucidate whether bone marrow cells ameliorate the
utcomes of myocardial ischemia by reduction of cell death and to investigate
hether the benefit is mediated by activation of intracellular kinases.
ethods: Muscles from the right atrial appendage of patients were subjected to 90
inutes of normothermic simulated ischemia followed by 120 minutes of reoxygen-
tion. Bone marrow cells from the same patients were co-incubated (105 cells per
illigram of tissue) with the muscles during the entire experimental period. Some
roups were treated with the protein kinase C inhibitor chelerythrine (10 mol/L) or the
38 mitogen-activated protein kinase inhibitor SB203580 (10 mol/L). Creatine kinase
eleased into the media during the reoxygenation period was measured (international
nits per milligram of wet tissue), cell death by necrosis was assessed by propidium
odide, and cell death by apoptosis was assessed by deoxyuride-5=-triphosphate biotin
ick end labeling (percentage of aerobic control values).
esults: Creatine kinase release was significantly reduced (from 1.30 IU/mg wet
issue  0.11 to 0.33 IU/mg wet tissue  0.06; P  .05), and cell death by necrosis
nd apoptosis was abolished by bone marrow cells (from 30.1%  7.3% and 28.1%
3.9% to 5.6%  5.1% and 3.7%  5.0%, respectively; P  .05), an effect that
as reversed by chelerythrine (13.4% 4.4% and 24.6% 8.2%, respectively) and
y SB203580 (20.1%  2.4% and 19.5%  5.7%, respectively).
onclusions: Bone marrow cells have a potent effect against cell death of the human
yocardium in the acute phase of ischemia that may explain, at least in part, the
mprovement in cardiac function and the reduction in infarct size seen when bone
arrow cells are injected after a myocardial infarction. These findings may have
mportant clinical implications to optimize cell therapy with bone marrow cells. In
ddition, the identification that the anti-ischemic effect of bone marrow cells is
ediated by the kinases protein kinase C and p38 mitogen-activated protein kinase
s also clinically relevant; it suggests that some of the beneficial effect of bone
arrow cells can be obtained by the activation of intracellular signaling molecules,
ithout the need for cell injection.
schemic heart disease accounts for more than 50% of the reported cases of heart
failure,1 which is the leading cause of morbidity and mortality in the W
world, affecting 4.8 million people in the United States2 and at least 10 millioeople in countries represented by the European Society of Cardiology.3 Therapies
iovascular Surgery ● November 2006
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Puch as thrombolysis and coronary angioplasty have im-
roved the clinical outcomes after an acute myocardial
nfarction; however, the incidence of heart failure continues
o increase.4 With the exception of heart transplantatio
here is no effective treatment for heart failure, and therefore
here is a need for effective new therapeutic interventions.
ecently, it has been suggested that repair/regeneration of
eart muscle by autologous adult stem cells may be an
ffective way of reversing heart failure. Bone marrow cells
BMCs) are readily available from the patient’s own bone
arrow, and they are inexpensive and easily prepared.
urthermore, they do not need to be expanded in culture,
nd their application does not require additional health
esources. Because of this, BMCs can be a very attractive
ool of cells for cardiac repair, and after the initial demon-
tration of safety use,5-9 several randomized clinical studie
re under way.
Animal and clinical studies have reported that the intra-
oronary or intramyocardial injection of BMCs after a myo-
ardial infarction improves the recovery of cardiac function
nd reduces infarct size.5-12 However, whether this effec
ccurs by differentiation of the BMCs into vessels and
uscle has been questioned.13,14 The observation tha
MCs can spontaneously fuse with other cells and subse-
uently adopt the phenotype of the recipient cells15,16 could
e an alternative mechanism of tissue repair, but this phe-
omenon may occur at too low a rate to be meaningful17 and
as been disputed by some investigators.18 Recently,
e19,20 and others21,22 have reported that progenitor or ste
ells may exist within the heart, and yet another potential
xplanation for the beneficial effect of BMCs on the heart
ould be that they promote the proliferation of resident
utative stem cells. Other investigators have also shown that
MCs decrease the expression of proapoptotic proteins and
educe apoptosis,23-25 although it is unclear from tho
tudies whether the antiapoptotic effect is the result of
ncreased angiogenesis and a better blood supply to the
schemic areas or is due to a direct effect of BMCs by
riggering intrinsic cardioprotective mechanisms. In this
onnection, it has been shown that BMCs segregate growth
actors and cytokines26 that in turn can activate antiapo-
otic intracellular signaling pathways.27,28 These mecha-
isms are not necessarily exclusive, but a full clarification of
Abbreviations and Acronyms
BMC  bone marrow cell
MAPKmitogen-activated protein kinase
PKC  protein kinase C
SI/R  simulated ischemia followed by
reoxygenationhe underlying cause of BMC-induced improvement in car- (
The Journal of Thoraciciac function is needed to refine their clinical application
nd maximize their therapeutical potential. Therefore, we
ought to elucidate whether BMCs protect the human myo-
ardium from ischemic injury by reducing cell death and to
nvestigate whether the benefit is mediated by activation of
he kinases protein kinase C (PKC) and p38 mitogen-
ctivated protein kinase (MAPK), by using a model of
imulated ischemia previously characterized in our
aboratory.29
ethods
tudy Patients and Experimental Preparation
he study was approved by the local ethics committee, and written
onsent was obtained from each patient. The right atrial appendage
as obtained from patients undergoing elective heart surgery. The
xperimental preparation used has been previously validated in our
aboratory.29 Briefly, upon harvesting, samples were immediat
mmersed in cold (4°C) Krebs/Henseleit N-2-hydroxyethylpiperazine-
-2-ethanesulfonic acid–buffered medium (118 mmol/L NaCl, 4.8
mol/L KCl, 27.2 mmol/L NaHCO3, 1 mmol/L KH2PO4, 1.2
mol/L MgCl2, 1.25 mmol/L CaCl2, 10 mmol/L glucose, and 20
mol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid) pre-
ubbled with 95% oxygen/5% carbon dioxide (pH 7.4). Muscles were
mmediately sectioned manually with a skin-graft blade (Swann-
orton Ltd, Sheffield, UK) to slices 300 to 500 m thick and
eighing 30 to 50 mg. After equilibration under normothermic aer-
bic conditions (95% oxygen/5% carbon dioxide) for 45 minutes,
uscles were subjected to 90 minutes of simulated ischemia (37°C),
btained by bubbling the media with 95% nitrogen/5% carbon diox-
de in the absence of glucose and at pH 6.8, followed by 120 minutes
f reoxygenation.
spiration of Bone Marrow and Preparation of
arrow Cells
ith patients under anesthesia and immediately before the initia-
ion of the operation, 40 mL of bone marrow was aspirated from
he iliac crest of the same patients donating the atrial appendage by
sing a bone marrow–harvesting needle (Medical Device Tech-
ologies Inc, Gainesville, Fla). The mononuclear fraction was
btained by density gradient. Cells were washed twice and sus-
ended in Krebs/Henseleit medium. The cells were then manually
ounted by using the Neubauer chamber.
tudy Groups
fter equilibration, the muscle slices were randomly allocated to the
ollowing groups (n 6 per group): (1) simulated ischemia followed
y reoxygenation (SI/R), (2) SI/R co-incubated with BMCs (105 cells
er milligram of tissue), (3) SI/R with the PKC inhibitor chelerythrine
10 mol/L), and (4) SI/R with BMCs and the PKC inhibitor chel-
rythrine (10 mol/L). Time-matched aerobic controls were used for
ach experiment. Similar experiments were performed by substituting
helerythrine by the p38 MAPK inhibitor SB203580 (10 mol/L).
oth chelerythrine and SB203580 were obtained from Calbiochem
td (Lutterworth, UK).
Commercially available human umbilical vein endothelial cells
nd keratinocytes were purchased from Cambrex Bioscience
Berkshire, UK). The cells were grown in culture and used after a
and Cardiovascular Surgery ● Volume 132, Number 5 1113
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CSPew passages. On the day of the experiment, cells were passaged
nd counted. A total of 105 cells per milligram of tissue were
ncubated with endothelial cells and keratinocytes in addition to
MCs in separate groups (n  4 per group).
ssessment of Tissue Injury
issue injury was assessed by measurement of creatine kinase
elease into the media during the 120-minute reoxygenation pe-
iod. The enzyme activity was measured by a linked-enzyme
inetic assay by using a commercial assay kit (30-3060/R2; Abbott
aboratories, Diagnostic Division, Kent, UK) and a plate reader
Benchmark; Bio-Rad Laboratories, Hercules, Calif). Results were
xpressed as international units per milligram of wet weight after
ubtraction of the aerobic control values.
ssessment of Cell Death
t the end of the experimental protocol, tissues were incubated for
minutes on ice with 5 g/mL propidium iodide in 0.1 mol/L
risodium citrate and 20 mmol/L phosphate-buffered saline at pH
.4 to identify the necrotic nuclei. After this, the muscles were
mbedded with optical cutting temperature embedding matrix,
issue-Tek (Agar Scientific Ltd, Essex, UK). Frozen sections were
hen cut at 8-m thickness in a Bright cryotome (model OTF,
right Instrument Co Ltd, Huntingdon, Cambridgeshire, UK)
t approximately 25°C, and sections were collected on
ECTABOND (Vector Laboratories Ltd, Peterborugh, UK)–
reated slides. To assess apoptosis, the sections were fixed with 4%
araformaldehyde, washed with 20 mmol/L phosphate-buffered
aline at pH 7.4 for 2 minutes, permeabilized in 0.02 mg/mL
roteinase K for 10 minutes at 37°C in a humidity chamber, and
resensitized for 1 minute in a microwave oven at 800 W in 0.1%
riton X-100 and 0.1 mol/L trisodium citrate at pH 6.0. Terminal
eoxynucleotidyl transferase was then used to incorporate fluores-
ein isothiocyanate–labeled deoxyuridine triphosphate oligonucleo-
ides to DNA strand breaks at the 3=-OH termini in a template-
ependent manner (deoxyuride 5=-triphosphate biotin nick end
abeling technique) by using a commercially available kit (Roche
iagnostics GmbH, Penzberg, Germany). Finally, to count the total
umber of nuclei, sections were mounted by using VECTASHIELD
ounting medium (Vector Laboratories) and stained with 4=,6-
iamidino-2-phenylindole.
To assess necrosis, propidium iodide–labeled nuclei were ex-
ited with helium-neon laser light at 543 nm, and fluorescence was
etected by using an emission range of 680 to 730 nm. For
poptosis, the fluorescein isothiocyanate fluorescence emission
ange used was 600 to 630 nm; it was then measured with argon
on fluorescence excitation at 488 nm and detected by laser con-
ocal epifluorescence microscopy.
Analysis was performed with NIH Image software (Scion Corp,
rederick, Md). Fluorescent signals with areas greater than 16 m2
ere counted to avoid the inclusion of artifact.
tatistical Analysis
ata were expressed as mean  SEM and subjected to analysis
f variance followed by post hoc t test comparison (Microsoft
xcel analysis tool pack; Microsoft Corp, Redmond, Wash). c
114 The Journal of Thoracic and Cardiovascular Surgery ● Novesults
s shown in Figure 1, A to C, substantial ischemic injur
as detected by creatine kinase release and by the degree of
ell necrosis and apoptosis. The figure also shows that
reatine kinase release was significantly reduced and that
ell necrosis and apoptosis were abolished in the groups
reated with BMCs, an effect that was reversed by the PKC
locker chelerythrine. Figure 1, D and E, shows represen
ative photomicrographs of necrosis and apoptosis for all the
tudy groups.
Figure 2, A to C , confirms the potent anti-ischem
ffect of BMCs seen in the previous study and demon-
trates that this benefit is also reversed by blockade of
38 MAPK with SB203580. Figure 2, D and E , also
hows representative photomicrographs of necrosis and
poptosis for all the study groups. The observed cardio-
rotective effect was specific for BMCs because, as
hown in Figure 3, the benefit could not be obtained
ndothelial cells and keratinocytes.
iscussion
e have demonstrated that BMCs possess potent cardio-
rotective properties against ischemic injury, with almost
omplete abolition of cell death by necrosis and apoptosis,
benefit that can be reversed by blockade of the kinases
KC and p38 MAPK. These results suggest that the bene-
cial effect of BMCs when injected after an acute myocar-
ial infarction is due, at least in part, to increased survival of
ardiac tissue. These findings are of importance for cell
herapy with BMCs, and their clinical relevance is discussed
elow.
There is experimental evidence that injection of BMCs
nto the infarcted myocardium improves cardiac function
nd reduces infarct size.10,11 More recently, there is indic-
ion that BMCs also ameliorate cardiac contractility in hu-
ans.5-9,12 However, it is not clear whether the mechan
f these beneficial effects from the BMCs involves prolif-
ration and differentiation of the injected cells, stimulation
f proliferation of putative resident stem cells, or a reduc-
ion of myocardial cell death. Animal11,30 and clinical6-9,12
tudies have suggested that BMCs can differentiate into
ardiomyocytes, although the capacity of hematopoietic
inage cells to differentiate into heart muscle has been
isputed.13,14 Although this mechanism could still play
ole in tissue repair, the capacity of BMCs to differentiate
nto cardiomyocytes may occur at a low frequency,31 and it
ight not be sufficient to fully explain the time course and
he degree of the benefit observed. Furthermore, few BMCs
emain in the heart after injection,32 which also question
he importance of proliferation and differentiation of BMCs
nto cardiomyocytes. Stimulation of putative resident stem
ells by BMCs may also play a role in the regeneration of
ardiac tissue, but, again, cells would require some time to
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Proliferate and fully differentiate into cardiomyocytes. Here
e have demonstrated for the first time that in humans,
utologous BMCs almost completely abolish myocardial
poptosis and necrosis induced by ischemia. Therefore, the
escue of cardiac tissue from dying may be a plausible
xplanation for the rapid improvement in function after the
dministration of BMCs. Our results seem to be specific for
MCs, because other cell types failed to afford cardiopro-
ection. The findings in human myocardium are supported
Figure 1. Creatine kinase (CK) release (A) and cell dea
myocardium (n  6 specimens per group) subjected
reoxygenation in the presence and absence of autologo
(10 pmol/L). *P < .05 versus the bone marrow (BM) gro
by staining with propidium iodide dye (red) and apopt
labeling technique (green). Necrotic nuclei were dete
stained nuclei and subtraction of the percentage of ney animal studies in which injection of fractionated BMCs e
The Journal of Thoraciclso reduced apoptosis and decreased the production
roapoptotic proteins.23-25 However, in these animal inve-
igations, it was not possible to separate whether the anti-
poptotic effect was caused by a direct action of the BMCs
r was the result of an improvement in blood supply to the
schemic areas by angiogenesis.
A second important finding of our study is that the
ardioprotection of BMCs can be reversed by blockade of
KC and p38 MAPK, thus suggesting that these kinases are
necrosis (B) and apoptosis (C) of human right atrium
minutes of simulated ischemia and 120 minutes of
Cs and the effect of PKC blockade with chelerythrine
epresentative photomicrographs showing necrosis (D)
(e) by the deoxyuride-5=-triphosphate biotin nick end
ed as a percentage of 4=,6-diamidino-2-phenylindole–
ic nuclei from control aerobic sections.th by
to 90
us BM
up. R
osis
rmin
crotssential factors in mediating the beneficial effect of these
and Cardiovascular Surgery ● Volume 132, Number 5 1115
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CSPells. In a rat model, Gnecchi and colleagues25 have also
uggested that Akt-modified mesenchymal stem cells im-
rove protection of the ischemic heart. It is worth noting
hat this intracellular signaling pathway of protection by
MCs is also shared by ischemic preconditioning in hu-
ans,33,34 another potent cardioprotective intervention th
er se may induce the recruitment of bone marrow–derived
Figure 2. Creatine kinase (CK) release (A) and cell
atrium myocardium (n  6 specimens per group) s
minutes of reoxygenation in the presence and abs
blockade with SB203580 (10 pmol/L). *P < .05 versu
crographs showing necrosis (D) by staining with
deoxyuride-5=-triphosphate biotin nick end labeling
a percentage of 4=,6-diamidino-2-phenylindole–stain
nuclei from control aerobic sections.ndothelial progenitor cells to the ischemic myocardium.35 o
116 The Journal of Thoracic and Cardiovascular Surgery ● Novonclusions
he results of this study may have important clinical impli-
ations for the treatment of ischemic heart disease and the
rogression to heart failure. They suggest that the adminis-
ration of BMCs may prevent myocardial injury and the
eath of tissue in the acute phase of a myocardial infarction,
t a time when massive myocardial necrosis and apoptosis
h by necrosis (B) and apoptosis (C) of human right
cted to 90 minutes of simulated ischemia and 120
of autologous BMCs and the effect of p38 MAPK
bone marrow (BM) group. Representative photomi-
idium iodide dye (red) and apoptosis (E) by the
nique (green). Necrotic nuclei were determined as
uclei and subtraction of the percentage of necroticdeat
ubje
ence
s the
prop
tech
ed nccur.36 Previously it has been suggested that a high ex-
ember 2006
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Pression of inflammatory factors in the early period of a
yocardial infarction may reduce the engraftment of
MCs,37 and, because of this, clinical trials have b
esigned to administer the BMCs 4 to 9 days after the
nfarction.6,7 Therefore, if BMCs act through a dual me-
nism, then it seems logical that they should be applied at
ore than one time point, initially to reduce the loss of
issue and later to initiate the repair/regeneration of the
efective heart muscle.
Our demonstration that the cardioprotection by BMCs
uring acute myocardial ischemia is mediated by PKC and
38 MAPK is also of clinical relevance because the same
eneficial effect could be obtained by selective pharmaco-
ogic activation of this signaling pathway without the need
or BMC administration. This is of special importance be-
ause during the first few hours of a myocardial infarction,
he aspiration of the marrow and the separation and injec-
ion of the cells may be logistically difficult and unpractical.
lthough these findings need to be confirmed in a clinical
etting, it is clear that this approach may reduce the myo-
ardial injury induced by ischemia in acute coronary syn-
romes and during cardiac surgery. However, it is worth
oting that we do not possess the means for the selective
anipulation of the kinase-mediated signaling cascades and
hat, at present, the safest clinical application may be the use
f autologous BMCs.
We thank the British Heart Foundation (PG/04/050) and Take
eart Leicester for their support and Nicola Harris for help with
he preparation of the manuscript. We are also grateful to Dr. Nick
igure 3. Creatine kinase (CK) release from human right atrial
yocardium (n 4 specimens per group) subjected to 90 minutes
f simulated ischemia and 120 minutes of reoxygenation in the
bsence and in the presence of autologous BMCs, human umbil-
cal vein endothelial cells, and human keratinocytes. *P < .05
ersus the other groups. IU, International units.aub (Trent RDSU) for statistical advice.
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